… effects on cardiovascular risk markers translate into … dapagliflozin to model the effect of
the drug on kidney and heart failure (HF) outcomes in patients with T2DM and impaired kidney …

… baseline risk marker, baseline risk marker-by-study interaction, and baseline … kidney
disease are needed to assess whether these risk marker changes, induced by dapagliflozin …

… Furthermore, beneficial effects on other cardiovascular risk markers have been reported …
effects of dapagliflozin on phosphate homeostasis independent of its effect on kidney function. …

… Assessment of the separate and combined effects of dapagliflozin and exenatide on kidney
variables was a prespecified secondary objective of the DECREASE study. The main study …

… the kidney effects of the SGLT2 inhibitor dapagliflozin in patients with proteinuric kidney …
The effects of long-term treatment with dapagliflozin on clinical kidney outcomes in patients …

… The purpose of this paper was to investigate the effects of dapagliflozin in chronic kidney …
Dapagliflozin reduced the risk of kidney failure and cardiovascular death/HF hospitalization …

… risk markers. Our study offers a first assessment on the exposure–response relationship for
dapagliflozin for other cardiorenal risk markers … the risk for heart failure and kidney outcomes …

… with chronic kidney disease. We aimed to investigate the effects of dapagliflozin on kidney,
… according to underlying cause of chronic kidney disease, reported as diabetic nephropathy, …

… beneficial effects of dapagliflozin on kidney and cardiovascular … loss of kidney function as
reflected by the eGFR slopes over time. … developed kidney failure requiring dialysis or kidney …

… Dapagliflozin, a selective sodium … risk markers, including body weight and blood
pressure.1, 2 Studies of SGLT2 inhibitors in patients with type 2 diabetes with and without kidney …